Diaceutics PLC Appointment of Head of Global Data
August 08 2019 - 1:02AM
RNS Non-Regulatory
TIDMDXRX
Diaceutics PLC
08 August 2019
Diaceutics PLC
("Diaceutics" or the "Company")
Appointment of Head of Global Data
Diaceutics PLC, (AIM: DXRX), a provider of data analytics and
implementation services to the global pharmaceutical industry,
announces that it has appointed Derek Hosty as Head of Global Data
with immediate effect. Derek will lead Diaceutics' data team as it
helps more patients across the world access precision medicine
drugs by driving better diagnostic testing through unique data
insights.
Diaceutics analyses significant volumes of data from worldwide
clinical laboratories conducting diagnostic tests that determine
which patients are eligible for specific precision medicine drugs.
The resulting insights are presented to pharmaceutical companies,
who then use the information to reach more patients.
Bringing almost 20 years of experience in software, analytics
and product development to the role, Derek will be responsible for
spearheading the Company's data strategy and the software tools to
support it, with an aim to give more patients the best possible
outcome. In doing so, Derek will drive further use of machine
learning and AI solutions that predict gaps in diagnostic care. He
will also lead the global data team in providing accurate, secure
and prompt insights that will result in better precision medicine
decisions.
Prior to this new role in Diaceutics, Derek was General Manager
for Cloud and Data at Irish software provider Openet, with a focus
on addressing specific business problems with analytics and machine
learning. He was also Director of Technology Strategy for Data and
Analytics at Norwegian telecommunications provider, Telenor Group,
with a principal focus on contextual marketing, data privacy and
security.
Ryan Keeling, Chief Innovation Officer, Diaceutics, said: "We
are leveraging the power of data to help break the industry mould
so that more people get access to potentially life-saving new
drugs. Our global data lake is expanding all the time and we are
constantly innovating to ensure we are using and analysing that
data in the most transformative way.
"Derek has a long track record of leading data & analytics
initiatives to achieve specific business goals. His broad knowledge
of software and machine learning will be crucial to ensuring we
consistently deliver game-changing insights that transform patient
healthcare."
Derek Hosty, Head of Global Data, Diaceutics, said: "Precision
medicine is one of the most exciting developments in healthcare to
date. However, it's not as effective as it should be because of low
testing rates, slow test turnaround times and inconsistent results.
Diaceutics realised early on that data can effect change and I look
forward to using my experience to help Diaceutics achieve its
mission to deliver seamless patient testing globally."
Enquiries:
Diaceutics PLC www.diaceutics.com
Peter Keeling, Chief Executive via Walbrook PR
Officer
Philip White, Chief Financial
Officer
Cenkos Securities plc (Nominated adviser
and broker) +44 (0) 20 3861 6630
Callum Davidson / Giles
Balleny
Michael Johnson (Sales)
Walbrook PR Tel: +44 (0)20 7933 8780 or diaceutics@walbrookpr.com
Anna Dunphy Mob: +44 (0)7876 741 001
Paul McManus Mob: +44 (0)7980 541 893
About Diaceutics
Diaceutics PLC is a leading diagnostics data analytics and
implementation services provider for global pharmaceutical
companies. The Company, quoted on the Alternative Investment Market
(AIM) of the London Stock Exchange, is enabling pharma to
accelerate their market penetration and achieve a better return on
precision medicine therapies by helping them to revolutionise
patient testing. By generating insights from its data lake of
clinical laboratory testing data and other data, Diaceutics helps
pharma understand and leverage the diagnostic landscape through
initiatives that improve patient testing, leading to better
treatment outcomes. The Company works with more than 30 global
pharmaceutical companies across hundreds of precision medicine
projects. The Company employs a leading global group of experts
from the laboratory, diagnostic and pharmaceutical industries.
www.diaceutics.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAUGUPARUPBGCM
(END) Dow Jones Newswires
August 08, 2019 02:02 ET (06:02 GMT)
Diaceutics (LSE:DXRX)
Historical Stock Chart
From Apr 2024 to May 2024
Diaceutics (LSE:DXRX)
Historical Stock Chart
From May 2023 to May 2024